Skip to main content
Equibles
AKBA logo

AKBA · Akebia Therapeutics, Inc. · Metrics

Track AKBA — free

Use AKBA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AKBA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.87 -0.01 (-0.69%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$244.05M
Shares
277.11M
Volume · Oct 2 7.11M Avg daily vol (3M) 6.07M

AKBA metrics

74 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.87
Market cap
$244.05M

Price action

20 metrics
Price change (1W)
-3.5%
Price change (30D)
-12.0%
Price change (3M)
-30.2%
Price change (6M)
-37.3%
Price change (YTD)
-46.3%
Price change (1Y)
-68.1%
Trailing year
Price change (5Y)
-69.4%
52-week high
$3.17
52-week low
$0.84
Change from 52-week high
-72.7%
Change from 52-week low
+2.5%
Annualized volatility
78.2%
Annualized volatility (3M)
75.7%
Beta
1.2
RSI (14D)
40.4
Price vs SMA 50
-12.1%
Price vs SMA 200
-29.7%
Avg volume (3M)
6.07M
Relative volume
1.2
Average dollar volume
$6.06M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
277.11M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.1×
reciprocal yield 89.8%
P / book
9.8
reciprocal yield 10.3%
FCF yield
16.5%
TTM · current market cap
Buyback yield
—
P / FCF
6.1
reciprocal yield 16.5%
P / operating cash flow
5.9
reciprocal yield 17.0%
Earnings yield
-12.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.7×
reciprocal yield 57.8%
EV / revenue historical average (5Y)
1.4×
reciprocal yield 72.9%
EV / EBIT historical average (3Y)
239.9×
reciprocal yield 0.4%
EV / EBIT historical average (5Y)
239.9×
reciprocal yield 0.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
79.6%
Operating margin
-6.9%
Trailing 12 months
Net margin
-13.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$15.13M
Net income (TTM)
−$29.67M
Trailing 12 months
Diluted EPS (TTM)
$-0.11
FCF margin
18.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$-2.21
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.12

Growth

11 metrics
Revenue growth YoY
-21.4%
Year over year
Net income growth YoY
-3,706.5%
Revenue (TTM)
$219.06M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-0.6%
Year over year · fewer shares
Revenue CAGR (3Y)
-6.9%
Revenue CAGR (5Y)
-4.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-118.6%
Return on assets
-8.5%
Debt / equity
2.0
Current ratio
1.4
EBITDA (TTM)
−$267.11M
Free cash flow (TTM)
$40.26M
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$155.55M
Total assets
$349.66M
Total debt
$49.56M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$41.55M
Capital expenditures (TTM)
$1.29M
R&D (TTM)
$70.46M
SG&A (TTM)
$113.79M
Stock compensation (TTM)
$13.31M
R&D / revenue
32.2%
Stock compensation / revenue
6.1%

Ownership (13F)

3 metrics
13F filers
171
13F filer change QoQ
-1
Institutional ownership
39.3%

Short interest

3 metrics
Short interest
7.4%
Latest settlement · 2.8 days to cover
Days to cover
2.8d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1517022 CUSIP 00972D105 13F (30d) 3 filings 3 filers Visit website Investor relations